hospitalization and roxithromycin (2 9 150 mg per os) afterwards. Primary study end-point was the rate of recurrences during follow-up; recurrence rates and their binomial 95% confidence intervals (CI) were calculated with SPSS 22.0. Recurrences were identified by (1) review of hospital records and (2) telephone questionnaires.
Results: Twenty-seven patients hospitalized for first lower limb cellulitis episodes were started on daptomycin and 26 patients completed the above three-week sequential treatment scheme.
During follow-up (range 37-85 months) one recurrence occurred among the 26 patients who completed the treatment: 96.2% of these patients remained relapse free at the end of follow-up (CI 79.5-99.9%). Considering also treatment failure, the overall effectiveness of this combination treatment was 92.6% recurrence free after more than 3 years follow-up (25/27 patients; CI 75.5-99.0%). This study is limited by retrospective planning and the restricted number of included patients. 
Conclusion

INTRODUCTION
Cellulitis is a common bacterial skin infection that involves the lower extremities in[70% of cases [1, 2] . Recurrences are frequent affecting 15-40% of patients in the first 3 years and constitute a significant risk factor for further disease episodes [1, 3] . 
DISCUSSION
With the present three-week treatment combination, in addition to a satisfactory ([95%) cure rate, we observed an optimistic low disease recurrence rate after more than 3 years follow-up. The present observation further supports our recent finding that the treatment of the first cellulitis episode with a 3 week clindamycin scheme may reduce the risk of subsequent recurrences [3] . Compared to conventional treatment selections cure rate of cellulitis with daptomycin are not inferior and due to once daily bolus administration, this agent could be also suitable for outpatient parental antibiotic therapy [6, 7] .
The pathogenesis of recurrent cellulitis episodes is still poorly understood [1, 2] .
Recurrent episodes of cellulitis generate functional residua in the affected skin area that predispose to subsequent disease episodes, thus creating a vicious cycle. To date the concept of modifying cellulitis recurrence risk by the selection of different treatment schemes for the first disease episode has not been adequately addressed. However, the treatment choice for the first cellulitis episode may confer protection against the risk of future relapses by different mechanisms: (1) Targeting bacterial protein synthesis by the antibacterial scheme could inhibit toxin synthesis and inflammatory mediators production during infection and thus protect tissues from excess damage (e.g., lymphedema perpetuation) [3, 4] ; (2) prolonged treatment duration ([2 weeks) may effectively eradicate latent infection foci in the relatively immunocompromised compartment of the tibial skin [8, 9] ; (3) It is further conceivable that the pathogenetic potential of the infecting bacterial strain, as denoted by the species and subspecies status, could variably predispose to subsequent relapses [10] . Daptomycin and roxithromycin target a broader species spectrum than traditional beta-lactam antibacterials.
This may be the first report of a long-term 
